INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients

Abstract

Objective Our objective was to determine if treatment with pravastatin prevents preeclampsia in pregnant patients at risk of preeclampsia.

Materials and Methods The study was performed in four major tertiary hospitals in Surabaya, Bandung, and Makassar between 2017 and 2021. Pregnant women at high risk of developing preeclampsia were recruited and randomized into an intervention group and control group. The control group received low-dose aspirin (80 mg) and calcium (1 g) daily, while the intervention group received additional pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery. The pregnancy was followed until delivery, and the clinical data were collected. The primary outcome was the occurrence of preeclampsia.

Result A total of 173 people participated in this study, including 86 in the control group and 87 in the pravastatin group. The pravastatin group had a significantly lower rate of preterm preeclampsia (13.8 vs. 26.7%; p = 0.034; odds ratio [OR] = 0.034, 95% confidence interval [CI] = 0.202–0.905) and preterm birth (16.1 vs. 36%; p = 0.003; OR = 0.340, 95% CI = 0.165–0.7), mostly indicated preterm birth. Preeclampsia occurred later in the pravastatin group than in the control group (36.39 + 2.32 vs. 34.89 + 3.38 weeks, p = 0.048). Overall, the pravastatin group showed better perinatal outcomes. Neonates with low Apgar scores (<7) at 1 minute (5.7 vs. 25.6%, p = 0.000) and 5 minutes (2.3 vs. 25.6%, p = 0.028) were significantly less common in the pravastatin group. Additionally, the rate of low birthweight babies (<2,500 g) was lower in the pravastatin group (27.6 vs. 40.7%; p = 0.069).

Conclusion Pravastatin (20 mg bid) significantly reduces the risk of preterm preeclampsia and preterm birth in women at a high risk of developing preeclampsia.

Key Points

• This is an open-label multicenter RCT to evaluate pravastatin effect to prevent preeclampsia.

• Pravastatin significantly reduces the risk of preterm preeclampsia (PE) and preterm birth in high risk PE women.

• Pravastatin had a beneficial effect on perinatal outcomes, including Apgar scores and birth weight.

Keywords

preeclampsia - pravastatin - maternal outcomes - perinatal outcomes - short-term health

Publikationsverlauf

Eingereicht: 23. Februar 2022

Angenommen: 11. März 2022

Accepted Manuscript online:
15. März 2022

Artikel online veröffentlicht:
06. Juni 2022

• References

• 1 Poon LC, Shennan A, Hyett JA. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 (Suppl. 01) 1-33
• 2 ACOG. Gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (76) 168-186
• 3 Brown MA, Magee LA, Kenny LC. et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72 (01) 24-43
• 4 Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol 2022; 226 (2S): S1171-S1181
• 5 Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol 2016; 11 (06) 1102-1113
• 6 Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ 2019; 366: l2381
• 7 Sibai B, Dekker G, Kupferminc M, Way AS. Pre-eclampsia. Lancet 2005; 365 (9461): 785-799
• 8 Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124 (07) 1094-1112
• 9 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365 (9461): 785-799
• 10 Levine RJ, Maynard SE, Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683
• 11 Redman CWG, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30 (suppl A): S38-S42
• 12 Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia. Am J Obstet Gynecol 2022; 226 (2S): S867-S875
• 13 Ahmed A, Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?. Br J Pharmacol 2015; 172 (06) 1574-1586
• 14 Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 2015; 213 (4, suppl): 9.e1, S9–S11
• 15 Kim S-Y, Ryu H-M, Yang J-H. et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007; 22 (05) 873-877
• 16 Reddy A, Suri S, Sargent IL, Redman CWG, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 2009; 4 (02) e4453
• 17 Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 2014; 101-102 (01) 153-160
• 18 Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochem Soc Trans 2009; 37 (Pt 6): 1237-1242
• 19 Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010; 74 (05) 818-826
• 20 Vahedian-Azimi A, Karimi L, Reiner Ž, Makvandi S, Sahebkar A. Effects of statins on preeclampsia: a systematic review. Pregnancy Hypertens 2021; 23: 123-130
• 21 Katsi V, Georgountzos G, Kallistratos MS. et al. The role of statins in prevention of preeclampsia: a promise for the future?. Front Pharmacol 2017; 8 (May): 247
• 22 Putra RA, Effendi JS, Permadi W, Bandiara R, Fauziah PN. Role of statin as inducer of Hmox-1 system in treatment of preeclampsia. Cell Mol Biol 2018; 64 (10) 1-4
• 23 Brownfoot FC, Tong S, Hannan NJ. et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 2015; 66 (03) 687-697 , discussion 445
• 24 Akbar MIA, Yosediputra A, Pratama RE. et al. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. J Matern Fetal Neonatal Med 2022; 35 (25) 5375-5382
• 25 Akbar MIA, Yosediputra A, Pratama RE. et al. INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and Its Effects on sFlt1/PlGF Levels. Am J Perinatol 2024; 41 (03) 300-309
• 26 Akbar MIA, Yosediputra A, Pratama RE. et al. INOVASIA Study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF Levels. Am J Perinatol 2024; 41 (03) 300-309
• 27 Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. 2014; 36 (06) 506-509
• 28 Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29 (11) 906-908
• 29 Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 2012; 72 (06) 773-788
• 30 Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64 (04) 496-509
• 31 Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29 (11) 906-908
• 32 Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. Elsevier; 2016. Accessed April 4, 2019 at: https://www.sciencedirect.com/science/article/pii/S1933287416302343
• 33 FDA. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins _ FDA. FDA Drug Safety Podcast. Published January 14, 2022. Accessed March 1, 2022 at: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
• 34 Costantine MM, Cleary K, Hebert MF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214 (06) 720.e1-720.e17
• 35 Ahmed A, Williams DJ, Cheed V. et al; StAmP trial Collaborative Group. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG 2020; 127 (04) 478-488
• 36 Winterfeld U, Allignol A, Panchaud A. et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013; 120 (04) 463-471
• 37 Costantine MM, Cleary K. Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric–Fetal Pharmacology Research Units Network*. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121 (2 Pt 1): 349-353
• 38 Costantine MM, West H, Wisner KL. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers (OPRC) Network, Bethesda, MD. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol 2021; 225 (06) 666.e1-666.e15
• 39 Itoh H. Obesity and risk of preeclampsia. Med J Obstet Gynecol 2014; 2 (02) 1024
• 40 Rocha RS, Alves JAG, Maia E Holanda Moura SB. et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med 2017; 45 (07) 843-849
• 41 Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32 (02) 138-146
• 42 Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 2014; 34 (07) 618-627
• 43 Lovgren TR, Dugoff L, Galan HL. Uterine artery Doppler and prediction of preeclampsia. Clin Obstet Gynecol 2010; 53 (04) 888-898
• 44 Antsaklis A, Daskalakis G. Uterine artery Doppler in the prediction of preeclampsia and adverse pregnancy outcome. Donald Sch J Ultrasound in Obs Gynecol 2010; 4 (02) 117-122
• 45 Pedroso MA, Palmer KR, Hodges RJ, Costa FDS, Rolnik DL. Uterine artery doppler in screening for preeclampsia and fetal growth restriction. Rev Bras Ginecol Obstet 2018; 40 (05) 287-293
• 46 ACOG Committee on Practice Bulletins–Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99 (01) 159-167
• 47 de Onis M, Habicht JP. Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. Am J Clin Nutr 1996; 64 (04) 650-658
• 48 Kupferminc MJ, Kliger C, Rimon E. et al. Pravastatin is useful for prevention of recurrent severe placenta-mediated complications—a pilot study. J Matern Fetal Neonatal Med 2021; 1-7
• 49 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97 (12) 1129-1135
• 50 Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J. et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101 (12) 2711-2719
• 51 Kumasawa K, Ikawa M, Kidoya H. et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108 (04) 1451-1455
• 52 Antonopoulos AS, Margaritis M, Shirodaria C, Antoniades C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012; 108 (05) 840-848
• 53 de Alwis N, Beard S, Mangwiro YT. et al. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. Pregnancy Hypertens 2020; 20: 83-91
• 54 Mendoza M, Ferrer-Oliveras R, Bonacina E. et al. Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study. Am J Perinatol 2021; 38 (14) 1472-1479
• 55 Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18 (11) 1519-1530
• 56 Girardi G. Can statins prevent pregnancy complications?. J Reprod Immunol 2014; 101-102 (01) 161-167
• 57 Akbar MIA, Yosediputra A, Pratama RE. et al. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. J Matern Fetal Neonatal Med 2022; 35 (25) 5375-5382
• 58 Bateman BT, Hernandez-Diaz S, Fischer MA. et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035
• 59 Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008; 146A (20) 2701-2705
• 60 Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39 (06) 397-412
• 61 Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv 2018; 73 (01) 40-55